Products & Services · Revenues:

Paxlovid — Revenues:

Pfizer Paxlovid — Revenues: decreased by 84.8% to $186.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.1%, from $491.00M to $186.00M.

Analysis

StatementSegment
First reportedQ3 2022
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Revenue
Metric ID: pfe_segment_paxlovid_revenues

Historical Data

11 periods
 Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$7.51B$4.07B$143.00M$202.00M$2.04B$251.00M$2.70B$491.00M$427.00M$1.23B$186.00M
QoQ Change-45.8%-96.5%+41.3%+907.4%-87.7%+976.9%-81.8%-13.0%+186.9%-84.8%
YoY Change-97.3%-50.0%+75.5%>999%-75.9%+70.1%-54.7%-62.1%
Range$143.00M$7.51B
CAGR-77.2%
Avg YoY Growth+130.5%
Median YoY Growth-52.3%

Frequently Asked Questions

What is Pfizer's paxlovid — revenues:?
Pfizer (PFE) reported paxlovid — revenues: of $186.00M in Q1 2026.
How has Pfizer's paxlovid — revenues: changed year-over-year?
Pfizer's paxlovid — revenues: decreased by 62.1% year-over-year, from $491.00M to $186.00M.